2016 TLC Speaker Biographies
Jeffrey Bland, PhD
Jeffrey Bland has been an internationally recognized leader in the nutritional medicine field for over 35 years and is known for his ability to synthesize complex scientific concepts in a manner that is both personable and accessible. A biochemist by training, Dr. Bland earned dual degrees in biology and chemistry from the University of California, Irvine, and completed his PhD in organic chemistry at the University of Oregon. He is a Fellow of both the American College of Nutrition where he is a Certified Nutrition Specialist and the Association for Clinical Biochemistry.
Dr. Bland has authored five books on nutritional medicine for the healthcare professional and six books on nutrition and health for the general public including The Disease Delusion: Conquering the Causes of Chronic Illness for a Healthier, Longer, and Happier Life (HarperWave, 2014). He is also the principal author of over 120 peer-reviewed research papers on nutritional biochemistry and medicine.
With his wife, Susan, Dr. Bland founded The Institute for Functional Medicine in 1991, a nonprofit organization focused on educating healthcare practitioners on effective approaches to treating and preventing chronic disease. During his decades-long career, Dr. Bland has traveled annually throughout North America, Europe, and Asia presenting a highly regarded seminar series on science-based nutrition and health. He has provided lectures and medical education events to more than 250,000 health care providers in more than 50 countries.
Dr. Bland was the founder and Chief Executive Officer of HealthComm International, a global company that became a leader in the development of medical foods in the 1990s. After a merger in 2000, Dr. Bland served as Chief Science Officer of Metagenics, Inc., and President of MetaProteomics from 2000 to 2012.
In 2012, Dr. Bland founded the Personalized Lifestyle Medicine Institute (PLMI), a nonprofit organization based in Seattle, Washington. In parallel, chronic disease is on the rise worldwide while discoveries in genomics and medical technologies are advancing rapidly. Medicine is poised for change in the 21st century, driven by a movement of informed and motivated consumers, and PLMI seeks to be a virtual meeting place and information source for this community of change agents.
Dr. Bland lives in Seattle, Washington with his wife Susan. His three sons and their families that include five grandchildren and his mother live nearby. He and his wife are avid boaters and have voyaged more than 40,000 miles in their own boats exploring Alaska and the waters of the Pacific Northwest. They spend a part of each year in Hawaii where ocean swimming, scuba diving and stand-up paddle in surfing are his hobbies. He has been a member of the Kona Ironman water safety team for the past four years.
Thomas Brown, MD, MBA
Thomas Brown, MD, MBA serves as Executive Director of the Swedish Cancer Institute and as the Co-Chair of the Cancer Leadership Council for Providence Health & Services. Dr. Brown has served as professor of medicine and COO of the University of Arizona Cancer Center, and on the faculty of the University of Texas MD Anderson Cancer Center and Duke University. He holds a Bachelor of
Arts degree from The Johns Hopkins University, and an MBA from Rice University. A graduate of the Medical College of Virginia, Dr. Brown completed an internal medicine residency at the University of Florida and a fellowship in medical oncology at The Johns Hopkins University School of Medicine. Dr. Brown’s clinical practice and research have focused on therapeutic development in gastrointestinal malignancies. His professional and academic interests include healthcare administration and policy, as well as international healthcare delivery systems. Dr. Brown serves on numerous boards, to include: Institute for Systems Biology; P4 Medicine Institute; American Cancer Society Great West Division; The Marsha Rivkin Center for Ovarian Cancer Research; and the Susan G. Komen, Puget Sound.
Michael Conte, MD
Dr. Michael Conte received his medical degree in 1986 from Albert Einstein College of Medicine. He completed his surgical residency at New York Hospital-Cornell Medical Center in 1993, which included a two year research fellowship at Brigham and Women’s Hospital (BWH) and Massachusetts Institute of Technology in Boston. He completed his vascular surgery training in 1994 as the John Homans Fellow at BWH and Harvard Medical School (HMS), in Boston. Dr. Conte was an Assistant Professor of Surgery at Yale University from 1994-1997, and a member of the Boyer Center for Molecular Medicine. He returned to BWH where he served as Assistant Professor (1997-2001) and then Associate Professor (2001-2008) of Surgery at HMS. From 2002-2008, he was the Director of Vascular Surgical Research at BWH and from 2005-2008, he was Co-Director of the Clinical Trials Group at the Center for Surgery and Public Health.
In 2008, Dr. Conte assumed the role of Chief of Vascular and Endovascular Surgery at the University of California, San Francisco (UCSF) Medical Center. He is Professor of Surgery and holds the E.J Wylie Chair in Vascular Surgery. He also serves as Co-Director of the UCSF Heart and Vascular Center, the Director of the Noninvasive Vascular Laboratory, and the Co-Director of the UCSF Center for Limb Preservation.
Dr. Conte’s clinical interests include diseases of the aorta, carotid artery disease, and peripheral artery disease (PAD). He is particularly interested in diabetic vascular disease, and in complex revascularization to preserve limb function and prevent amputation in patients with critical ischemia. He led the largest multicenter clinical trial to date examining the outcomes of vein bypass surgery in patients with severe PAD, and is nationally and internationally recognized for his leadership in this area.
Dr. Conte’s translational research program includes basic laboratory investigations as well as human studies, focused on understanding and improving the healing response of blood vessels following angioplasty and bypass surgery. His work is funded by the National Institutes of Health.
Dr. Conte is a member of many professional organizations, including the Society for Vascular Surgery, the American Surgical Association, and the Society of University Surgeons. He has been an invited lecturer for many regional, national, and international conferences. In 2006, he received the Distinguished Achievement Award from the New York Weill Cornell Medical Center Alumni Council. He has served on multiple editorial boards including Circulation and the Journal of Vascular Surgery. He is currently serving as Chair of the American Heart Association Council on Peripheral Vascular Disease. He also serves as Chief Medical Officer of the non-profit foundation Vascular Cures.
Anita Goel, MD, PhD
Dr. Anita Goel, MD Ph.D is Chairman, CEO and Scientific Director of the Nanobiosym Research Institute as well as Nanobiosym Diagnostics. Dr. Goel, a world-renowned nanotechnology expert in the emerging field of Nanobiophysics – a new science at the convergence of physics, nanotechnology, and biomedicine. A Harvard-MIT trained physicist-physician, inventor, and global entrepreneur, Dr. Goel has harnessed over 20 years of her research in nanomachines that read and write information in DNA to develop Gene-RADAR® – and was awarded the first XPRIZE ever to be given for healthcare. Gene-RADAR® is a platform for personalized, precision medicine: the first tricorder device that can diagnose any disease or DNA/RNA biomarker in real-time with gold-standard accuracy in a mobile device. Dr. Goel was named one of the “World’s Top 35 Science and Technology Innovators” by MIT’s Technology Review and one of the “World’s Most Influential Visionaries in Biotech” by Scientific American. Through her Nanobiosym Research Institute, Dr. Goel is pioneering new physics insights into the way genes are “read” and how this process can be influenced by their molecular environment, and how quantum mechanics might play a “nontrivial” role. She and her team at Nanobiosym and an ecosystem of global collaborators are building new apps for the Gene-RADAR® platform for next generation molecular diagnostics, drug discovery, personalized precision nanomedicine and wellness.
Patrick Hanaway, MD
PATRICK HANAWAY, MD is a board-certified family physician with his medical degree from Washington University and residency training at the University of New Mexico. Dr. Hanaway is on the Executive Committee for the newly formed American Board of Integrative Medicine and is Past President of the American Board of Integrative Holistic Medicine. He co-founded Family to Family: Your Home for Whole Family Health with his wife in Asheville, NC. Dr. Hanawayhas been initiated as a Marakame (Shaman) by the Huichol people in the Sierra Madres of Central Mexico and serves as Chairman of the Board of Blue Deer Center, a non-profit retreat in upstate New York.
Dr. Hanaway has a unique perspective on functional medicine. As Chief Medical Officer of Genova Diagnostics for a decade, he developed expertise in the clinical application of nutritional biochemistry, with an emphasis on digestive disease and nutritional assessment—subjects that have great relevance to functional medicine. The Institute for Functional Medicine (IFM) appointed Dr. Hanaway to Director of Medical Education in May of 2012; he now holds the role of Chief Medical Education Officer and oversees the development and implementation of IFM’s educational programs worldwide.
In 2014, Dr. Hanaway helped develop the collaboration between IFM and the Cleveland Clinic, where he now serves as the Medical Director of the Center for Functional Medicine. His current work in Cleveland is creating a multi-disciplinary team-based model of holistic care delivery, overseeing six studies in comparative effectiveness research,fostering community outreach, and promoting educational change throughout the Cleveland Clinic.
Dr. Hanaway currently serves on the Editorial Boards of Integrative Medicine: A Clinician’s Journal; Journal of Alternative and Complementary Medicine; Global Alternatives in Health and Medicine;and a new journal Brain and Gut.
Dr. Hanaway teaches extensively on holism and systems medicine, in its many applications. His interests are in the continued development of health care delivery models that learn from traditional medical systems and promote research to demonstrate improved value in patient outcomes. Dr. Hanaway teaches on the clinical application of nutritional biochemistry, with an emphasis on digestion, immunology, mitochondrial function, and wellness.
Mark Hyman, MD
Dr. Hyman is a practicing family physician, a 10-timeNew York Times bestselling author, and an internationally recognized leader, speaker, educator, and advocate in the field of Functional Medicine. He is the Pritzker Foundation Chair in Functional Medicineat the Cleveland Clinic Lerner College of Medicine and Director of the Cleveland Clinic Center for Functional Medicine. He is Founder and Director of The UltraWellness Center, chairman of the Institute for Functional Medicine, medical editor of The Huffington Post, and a regular medical contributor in the media for CBS This Morning, Good Morning America, CNN, The Dr. Oz Show, and more.
Marcia Kean, MBA
Marcia Kean has been deeply engaged in the transformative side of biomedicine for 30+ years, working closely with pioneers in industry, academe and government on policy and strategy. Much of her current work is focused on multi-stakeholder policy initiatives to support patient-centeredness as critical to high quality clinical care. Marcia established the nation’s first Molecular Medicine communications practice, and played a key role in the establishment and development of the Personalized Medicine Coalition.
Marcia has been deeply embedded in the cancer field for decades. She worked with the National Cancer Institute, advising on communications for its Advanced Technology Initiatives in genomics, proteomics and informatics. She is the originator and Chair of the Turning the Tide Against Cancer through Sustained Medical Innovation initiative, that identifies and advocates for policy that supports biomedical advances.She serves on the Board of Trustees of CancerCare, the leading national organization providing free, professional support services and information to help people manage the emotional, practical and financial challenges of cancer. Marcia was a catalyst for the formation of iConquerMS™, a patient-powered research network, and leads its communications activities.
Marcia holds an M.B.A. from New York University and a B.A. from the University of California at Berkeley.
Rob Knight, PhD
Rob Knight is Professor of Pediatrics and Computer Science & Engineering at the University of California, San Diego, and author of “Follow Your Gut: The Enormous Impact of Tiny Microbes”. He received a B.Sc. in Biochemistry in 1996 from the University of Otago in his native New Zealand, a PhD in 2001 from Princeton University in Ecology and Evolutionary Biology, and performed postdoctoral work at the University of Colorado, Boulder before becoming a faculty member in the interdisciplinary BioFrontiers Institute there in 2004. He moved to UC San Diego in 2015 to direct the new Microbiome Initiative. His work focuses on using readout technologies such as next-generation sequencing to improve our understanding of the structure, function and dynamics of the human microbiome, contributing to the main data analysis in the NIH-funded Human Microbiome Project. He is co-founder of the Earth Microbiome Project and the American Gut Project. Current research interests include relating the human microbiome to diseases ranging from obesity to mental illness, spatial and temporal mapping of microbial communities on different scales ranging from our bodies to our planet, and developing new data visualization methods that assist in resolving the challenge of microbial “Big Data”.
Daniel Kraft, MD
Dr. Kraft has over 20 years of experience in clinical practice, biomedical research and healthcare innovation. Daniel is the Faculty Chair for Medicine & Neuroscience for Singularity University and is Founding Executive Director for Exponential Medicine, a program which explores convergent, exponentially developing technologies and their potential in biomedicine and healthcare. His various TEDTalks have over 1 Million Views.
Following undergraduate degrees at Brown University and medical school at Stanford, Dr. Kraft was board certified in the Harvard combined Internal Medicine and Pediatrics residency program at the Massachusetts General Hospital and Boston Children’s Hospital. He went on to complete Stanford fellowships in hematology/oncology & bone marrow transplantation, and extensive research in stem cell biology and regenerative medicine. He has multiple scientific publications (Nature and Science) and medical device, immunology and stem cell related patents through faculty positions with Stanford University School of Medicine and as clinical faculty for the pediatric bone marrow transplantation service at University of California San Francisco.
Dr. Kraft is the inventor of the MarrowMiner, an FDA approved device for the minimally invasive harvest of bone marrow, and founded RegenMed Systems, a company developing technologies to enable adult stem cell based regenerative therapies. Dr. Kraft also founded IntelliMedicine.
Edward Lin, MD
Dr. Lin is the chief medical officer of P4 Medicine Institute founded by Dr. Lee Hood. He is also an associate professor of medicine at the University of Washington, Associate member of Fred Hutchinson Cancer Research Center. He serves as a member of NCCN colorectal cancer guideline committee as well as SWOG GI committee. He also served under UICC Sino-US Hem-Onc visiting scholar program committee. Dr. Lin is a world renowned GI medical oncologist with special interests in colorectal cancer research especially on cancer stem cells and endothelial progenitors. He was elected America’s top physician in 2005 and was voted as the 2014 Cancer Research Year Award. He pioneered ADAPT treatment and monitoring protocol for advanced colorectal cancer that had dramatically improved patients survival and held 4 patents issued by MD Anderson Cancer Center and University of Washington. Prior to his appointment at UW, he was an assistant professor of medicine at the University of Texas MD Anderson Cancer Research Center from 2000-2006. Dr. Lin completed his medical school training in 1986 at China Medical University Sum Cum Laud in English Medical Class. He then studied Institute of Basic Medical Science under Professor Pei Hsien Tang, a pioneer in hematopoietic stem cells research in China from 1986-1989. He then studied at the Kenneth Norris Cancer research center and later took a senior research associate position at the Amgen, Inc where he participated in the cloning of thrombopoietin. Dr. Lin completed his internal medicine training at Brown University of School medicine in 1997 hematology and oncology fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School under Dr. Steven Cannistra. Dr. Lin had published numerous papers, reviews and book chapters and abstracts. He is the Editor-In-Chief of the popular Cancer-matrix Manual and serves on the editorial board for Stem Cell, Translational Medicine. He is the currently the president of Seattle Biomedical Association and board of Washington Asian Health Professional Association.
Helen Messier, PhD, MD
Dr. Messier has a passion for integrating genomic, metabolomic, microbiomic, and environmental data into patient care. She is a pioneer and leader in providing precision medicine that deals with primary prevention and uncovering the root causes that lead to illness. Dr. Messier received a Bachelor of Science (Honors) in Genetics from the University of Alberta. Dr. Messier went on to earn a Ph.D. in Molecular Immunology from the University of Alberta with a focus on the genetic regulation of T-cell receptor genes. She completed post-doctoral studies at the La Jolla Institute for Allergy and Immunology in San Diego, California. She then received her MD and completed her residency in Family Medicine the the University of Calgary. Dr. Messier is the medical director of Healix Health, a practice aimed at bringing comprehensive testing into a concierge medical setting, is on the faculty of the Institute for Functional Medicine and is on the Advisory Board of Genome magazine. She is currently the Medical Director, Genomics at Human Longevity Inc. in San Diego California, and is a physician in the Health Nucleus, a clinical research facility which uses a suite of state of the art human genome sequencing, scanning and advanced testing technology to apply big data to personalized, precision medicine.
Siddhartha Mukherjee, MD, PhD
SIDDHARTHA MUKHERJEE, M.D., Ph.D. (D.Phil),is a cancer physician and researcher. He is an assistant professor of medicine at Columbia University and a cancer physician at the CU/NYU Presbyterian Hospital. A Rhodes Scholar, he graduated from Stanford University, University of Oxford, and Harvard Medical School and was a Fellow at the Dana Farber Cancer Institute and an attending physician at Massachusetts General Hospital and Harvard Medical School. THE EMPEROR OF ALL MALADIES, published by Scribner in 2010, was awarded the Pulitzer Prize for General Nonfiction, named one of the ten Best Books of 2010 by the New York Times Book Review, and is the basis for the PBS miniseries Cancer: The Emperor of All Maladies. He has published also articles in Nature, New England Journal of Medicine, Neuron, Journal of Clinical Investigation, The New York Times, The New York Times Magazine, and The New Republic. He lives in New York with his wife and daughters.
Michael Nova, MD, PhD
Dr. Nova is currently the Chief Innovation Officer of Pathway Genomics, and was a founding team member of the company. He is the inventor of the Pathway-IBM/Watson Machine Learning A.I. mobile application: Panorama/OME; and the entire Wellness (Pathway FIT/Healthy Weight, SkinFIT), Cardiac and Mental Health line of genetic testing products for Pathway. Dr Nova has executed major corporate alliances with companies such as Medco/ESI, PepsiCo, DASA (Brazil), Biogenetika (Brazil), Achibadem (Turkey), IHH/Parkway (Singapore), IBM, Florida Hospital Group, Equinox Health, and many others. His scientific career began as a research associate at the Salk Institute in the laboratory of Nobel Laureate Roger Guillemin, where he studied the genetics and proteomics of human growth factors and cancers. Michael was previously the founder and CEO of Discovery Partners Inc. (Nasdaq: DPII), which completed a successful $150M IPO and marketed wireless drug discovery technology and radiofrequency combinatorial chemistry to large pharmaceutical companies. Intellectual property developed by Dr. Nova at DPII included the original “barcode on bead” patents used by many diagnostic and DNA companies. He then founded the wireless sensory network company Graviton, where he was responsible for raising $60 million in capital from venture groups such as Kleiner Perkins, InQtel and large corporations such as Motorola and Qualcomm. Dr. Nova is also the 2005 World Economic Forum (WEF) Technology Pioneer Award Winner; and the physician of record on the first person ever to have their entire genome sequenced by Illumina (2009).
He is a member of the IBM Watson Advisory Board, the Metagenics Scientific Advisory Board, the Salk Institute NeuroAI group, and the Longevity Org Advisory Board.
Dr. Nova has over 30 issued, and 45 pending patents; and he has numerous publications in peer-reviewed journals. With degrees in Biochemistry, Physics/Computer Science, and Medicine, Dr. Nova is a Board-certified Dermatologist and Dermatopathologist licensed in California. In his minimal spare time, Michael likes to surf big waves in Indonesia and Mexico, and he also helped build a WHO-sanctioned basic care clinic in the Fijian town of Nabila.
Nathan Price, PhD
Dr. Nathan Price is Professor & Associate Director of the Institute for Systems Biology (ISB) in Seattle. He is co-PI with Lee Hood of ISB’s 100K Person Wellness Project, and is a Co-Founder and member of the Board of Directors of Arivale, a scientific wellness company. He has won numerous awards for his scientific work, including a Howard Temin Pathway to Independence Award from NIH, an NSF CAREER award, a young investigator award from the Roy J. Carver Charitable Trust, and he was named as one of the inaugural “Tomorrow’s PIs” by Genome Technology and, most recently, as a Camille Dreyfus Teacher-Scholar. Dr. Price serves on editorial boards for many leading scientific journals, including Science Translational Medicine and Cell Systems.
Erica Ramos, MS, LCGC
Erica Ramos, MS, LCGC is the clinical lead for Illumina’s “Healthy Genome Initiatives” team and is the 2017 President-Elect for the National Society of Genetic Counselors, the leading professional organization for genetic counselors more than 3000 members strong. She received her Master’s in Genetic Counseling from the University of California, Irvine in 2001. After graduation, she spent 11 years as a clinical genetic counselor, first in prenatal and preconceptional settings and then in cancer and adult-onset disorders. In 2012, Ms. Ramos joined Illumina in the Illumina Clinical Services Laboratory, where she managed the genetic counseling and variant curation teams that implemented the interpretation and reporting process for whole genome sequencing in healthy individuals and launched the lab’s undiagnosed disease offering. In her current role, she is focused on advancing the use of whole genome sequencing in clinical care by providing access and education to healthy individuals through the Understand Your Genome programs, MyGenome visualization software and other research and collaborations. She also tweets from @ERamosSD about genomics and genetic counseling, music, travel and Wisconsin sports, among other interests and sometimes her employer trusts her enough to live-tweet genomics events from @IlluminaLive.
Giselle Sholler, MD, MSC
Dr. Sholler is the Endowed Haworth Family Director of the Innovative Therapeutics Clinic and Director of Pediatric Oncology Research, at Helen DeVos Children’s Hospital. She is an Associate Professor at Michigan State University College of Human Medicine and the founder and chair of the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC). Within the NMTRC, she has initiated many Phase I and II trials for relapsed or refractory medulloblastoma and neuroblastoma patients as well initiating the first trials using Molecular Guided Therapy in children with relapsed cancers in collaboration with Dell and TGen. The NMTRC is an international collaborative team of 25 distinguished universities and children’s hospitals that have joined together to offer a national network of pediatric oncology clinical trials.
Susan Snodgrass, MD
Susan Snodgrass is a Senior Medical Director, Clinical Research and Medical Affairs at Juno Therapeutics. Dr. Snodgrass has over 10 years of experience in the pharmaceutical industry, most recently at Novartis where she helped develop the Signature personalized medicine trial. Prior to joining industry, Dr. Snodgrass was a practicing Neuro Oncologist and held academic appointments at the H. Lee Moffitt Cancer Center and Research Institute, Case Western Reserve University and the University of Miami, School of Medicine. Dr. Snodgrass graduated from the University Of Miami School Of Medicine and has degree in Pharmacy from the Ohio State University.